Supplementary Materials

Supplementary Material for:

MHC Class I–Associated Phosphopeptides Are the Targets of Memorylike Immunity in Leukemia

Mark Cobbold,* Hugo De La Peña, Andrew Norris, Joy M. Polefrone, Jie Qian, Ann Michelle English, Kara L. Cummings, Sarah Penny, James E. Turner, Jennifer Cottine, Jennifer G. Abelin, Stacy A. Malaker, Angela L. Zarling, Hsing-Wen Huang, Oliver Goodyear, Sylvie D. Freeman, Jeffrey Shabanowitz, Guy Pratt, Charles Craddock, Michael E. Williams, Donald F. Hunt, Victor H. Engelhard*

*Corresponding author. E-mail: m.cobbold@bham.ac.uk (M.C.); vhe@virginia.edu (V.H.E.)

Published 18 September 2013, Sci. Transl. Med. 5, 203ra125 (2013)
DOI: 10.1126/scitranslmed.3006061

This PDF file includes:

  • Fig. S1. Detailed HLA-binding motif analysis.
  • Fig. S2. Immunity against phosphopeptides in healthy donors is phosphate-dependent.
  • Fig. S3. T cell memory subset mapping of anti-phosphopeptide responses in healthy donors.
  • Fig. S4. Leukemia-associated phosphopeptide-specific immunity is lacking in CLL patients.
  • Fig. S5. Deletion (rather than anergy) of anti-phosphopeptide immunity in five patients with CLL.
  • Fig. S6. Leukemia-associated phosphopeptide-specific immunity is lacking in AML patients but restored after SCT.
  • Fig. S7. Immunocompetence of patients with AML in complete remission before transplantation.
  • Table S1. CLL patient characteristics.
  • Table S2. AML patient characteristics.

[Download PDF]